Press coverage about Jounce Therapeutics (NASDAQ:JNCE) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Jounce Therapeutics earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.067358608039 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

A number of research analysts recently commented on JNCE shares. Robert W. Baird restated a “buy” rating and set a $30.00 price objective on shares of Jounce Therapeutics in a research note on Tuesday, September 12th. Cowen and Company restated a “buy” rating on shares of Jounce Therapeutics in a research note on Friday, June 9th. Finally, Zacks Investment Research downgraded Jounce Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Jounce Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $23.67.

Shares of Jounce Therapeutics (JNCE) traded down 3.14% on Friday, reaching $17.26. The company had a trading volume of 226,138 shares. Jounce Therapeutics has a 12 month low of $14.39 and a 12 month high of $24.79. The firm’s market capitalization is $555.67 million. The company’s 50-day moving average is $15.54 and its 200 day moving average is $15.54.

Jounce Therapeutics (NASDAQ:JNCE) last posted its earnings results on Wednesday, August 9th. The company reported ($0.11) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.04. The company had revenue of $20.29 million for the quarter, compared to the consensus estimate of $19.94 million. During the same quarter last year, the business earned ($7.23) EPS. Equities analysts forecast that Jounce Therapeutics will post ($0.62) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Jounce Therapeutics (JNCE) Earns Media Impact Rating of 0.20” was reported by Watch List News and is the property of of Watch List News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.watchlistnews.com/jounce-therapeutics-jnce-earns-media-impact-rating-of-0-20/1613465.html.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.

Insider Buying and Selling by Quarter for Jounce Therapeutics (NASDAQ:JNCE)

Receive News & Ratings for Jounce Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.